Clinical practice guidelines and management options for adult obesity

Guideline principles

Current obesity management guidelines emphasise a comprehensive approach combining lifestyle intervention (dietary modification, physical activity), pharmacotherapy (increasingly effective options including GLP-1 receptor agonists), and bariatric surgery for severe obesity - with treatment intensity matched to obesity severity and associated comorbidity, moving beyond a lifestyle-advice-only approach for patients with significant obesity
A rapidly evolving area of clinical practice given the substantial recent expansion of effective pharmacotherapy options, meaningfully shifting the treatment landscape beyond what was available even a few years prior

Obesity is increasingly recognised and managed as a chronic disease with a complex, multifactorial pathophysiology (including neurohormonal appetite regulation, see ) rather than simply a matter of insufficient willpower or lifestyle discipline - this reframing underlies the shift toward treating obesity with the same chronic-disease-management principles (combination therapy, ongoing treatment rather than a finite course, treatment intensity matched to severity) applied to other chronic conditions

BMI and waist circumference/waist-to-hip ratio (see and related notes) alongside comorbidity assessment inform treatment intensity matching
Comprehensive assessment should include screening for obesity-related comorbidities (see ) which themselves may independently influence treatment urgency and approach

Lifestyle intervention remains foundational at every severity level, but is now recognised as insufficient alone for many patients with significant obesity
Pharmacotherapy (including newer, substantially more effective incretin-based agents) is increasingly used earlier and more readily for appropriate candidates, reflecting improved efficacy and tolerability compared with older options
Bariatric surgery remains the most effective option for severe obesity with significant comorbidity, per the criteria discussed in

GLP-1 receptor agonists and the substantial recent shift in obesity pharmacotherapy efficacy, obesity reframed as chronic disease requiring ongoing (not finite-course) management, treatment intensity matching to severity/comorbidity, combination approach across lifestyle/pharmacotherapy/surgery
Obesity management has shifted meaningfully in recent years with substantially more effective pharmacotherapy options becoming available, moving treatment approach away from lifestyle-advice-alone even for moderate obesity toward a chronic-disease-management model combining lifestyle intervention with pharmacotherapy (and, for severe cases, surgery) matched to individual severity and comorbidity - a genuine, clinically significant evolution from older, more limited treatment paradigms

4 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.